Q-omics provides the consensus-scored FAM221B profile across patient tissues and cancer cell-line models. FAM221B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM221B is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM221B RNA expression shows 15,078 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where FAM221B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM221B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM221B survival associations across molecular data types. FAM221B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM221B RNA expression–survival associations across cancer types. High FAM221B expression shows unfavorable associations in LIHC, but favorable associations in BLCA, PAAD, LGG, UCS and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM221B RNA expression.
This table summarizes FAM221B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM221B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM221B shows lower tumor expression in KIRC, LUSC and LUAD and higher tumor expression in LIHC, THCA and KICH. The KIRC box plot shows higher FAM221B RNA expression in normal versus tumor tissue (log2 FC = −0.045, t-test p < 0.001).
This table shows molecular features associated with FAM221B in patient tissues and cancer cell lines. In patient samples, FAM221B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM221B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
